FDA grants iStar Medical IDE for glaucoma implant pivotal trial

iSTAR Medical receives U.S. FDA approval to start pivotal trial for ...

WAVRE, Belgium — 15 July 2021: iSTAR Medical, a med-tech company developing minimally-invasive implants for glaucoma surgery (MIGS), ...

iSTAR Medical announced today that the FDA granted investigational device exemption to start a pivotal trial with its MINIject implant.

iSTAR Medical receives U.S. FDA approval to start pivotal trial for ...

WAVRE, Belgium, July 15, 2021 /PRNewswire/ -- iSTAR Medical, a med-tech company developing minimally-invasive implants for glaucoma surgery ...

iSTAR Medical receives US FDA approval to start pivotal

iSTAR Medical, a med-tech company developing minimally-invasive implants for glaucoma surgery (MIGS), announced today that the U.S. Food and ...

iSTAR Medical gets FDA nod to initiate trial of MINIject for glaucoma

iSTAR Medical has received investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to commence a clinical trial of its minimally ...

iSTAR Medical shows initial positive progress of US STAR-V trial for ...

Pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US · Positive feedback from world-leading glaucoma surgeons involved in ...

FDA Grants Approval to iSTAR Medical for Clinical Trial for MINIject

The U.S. Food and Drug Administration (FDA) has granted iSTAR Investigational Device Exemption (IDE) approval for to begin a trial with ...

Conventional glaucoma implants and the new MIGS devices

Hydrus® Microstent (Ivantis, Inc.) CE mark granted in 2011, FDA approved since 2018, 37.1% at 1 year (Prospective, randomised clinical trial) [30].

FDA Webview

iStar Medical Glaucoma Implant Trial OKd. [ Price : $8.95]. FDA grants iStar Medical an IDE to begin a pivotal trial with its Miniject implant in over 350 ...

iStar Medical conducts first MINIJect procedures in Ireland

... iSTAR Medical's mission to preserve the vision of glaucoma patients ... FDA grants iStar Medical IDE for glaucoma implant pivotal trial. Sean ...

iSTAR gains European approval for implant for glaucoma surgery

iSTAR Medical, a medtech company developing novel minimally-invasive implants for glaucoma surgery (MIGS), has seen its MIGS device, ...

ISTAR Medical Receives U.S. FDA Approval To Commence Pivotal ...

iSTAR Medical MINIject STAR-V study will investigate MINIjectTM in over 350 patients with primary open angle glaucoma.

AbbVie enters partnership with iStar with option to acquire

... clinical study, an FDA investigational device exemption (IDE) study. ... FDA grants iStar Medical IDE for glaucoma implant pivotal trial. Sean ...

iStar Medical to Begin Pivotal MIGS Trial - Glaucoma Physician

iStar Medical said the FDA granted it an Investigational Device Exemption to start a pivotal trial with the Miniject. The STAR-V study will ...

News and Resources from the WTWH Media Life Science Network ...

FDA grants iStar Medical IDE for glaucoma implant pivotal trial. iSTAR Medical announced today that the FDA granted investigational device exemption to start ...

iSTAR Medical shows initial positive progress of US STAR-V trial for ...

The pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US, has received positive feedback from glaucoma surgeons ...

FDA Approves First-of-its-Kind Glaucoma Treatment

The U.S. Food and Drug Administration has approved a new treatment for glaucoma, iDose® TR (travoprost intracameral implant, 75 mcg).

Surgical Augmentation of the Suprachoroidal Space - PubMed Central

MINIject (iSTAR Medical, Wavre, Belgium) is a 5 mm length microinvasive glaucoma drainage implant that targets the supraciliary pathway of ...

iSTAR - Recent News & Activity - Crunchbase

Drug Delivery Business — FDA grants iStar Medical IDE for glaucoma implant pivotal trial. News• Feb 18, 2021. NJBiz — Asbury Ocean Club is breaking sales ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ...

U.S. We submitted a PMA application to the FDA at the end of 2017 after completing the U.S. pivotal IDE clinical trial to evaluate the iStent Inject for the ...